Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached a copy of Company''s Q4 & FY23 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023, as approved by the Board of Directors in their meeting held on May 11, 2023. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith the Press Release on the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023. Dr. Lal PathLabs Ltd - 539524 - Corporate Action-Board approves Dividend
Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia recommended final dividend of Rs. 6/- per equity share (@ 60% on a face value of Rs. 10/- per share) for the year ended March 31, 2023 subject to approval of the Shareholders at the forthcoming Annual General Meeting ('AGM') of the Company. Information regarding record date for payment of final dividend, if any, will be intimated in due course. Dr. Lal PathLabs Ltd - 539524 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 11, 2023
Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia approved the following(s): 1. Recommendation of final dividend of Rs. 6/- per equity share (@ 60% on a face value of Rs. 10/- per share) for the year ended March 31, 2023 subject to approval of the Shareholders at the forthcoming Annual General Meeting ('AGM') of the Company. Information regarding record date for payment of final dividend, if any, will be intimated in due course; 2. Appointment of Mr. Vinay Gujral as Company Secretary (KMP) of the Company w.e.f. May 11, 2023; 3. Appointment of M/s Ernst & Young LLP (EY) as the Internal Auditors of the Company for the Financial Year 2023-24; 4. Appointment of M/s A.G. Agarwal & Associates as the Cost Auditors of the Company for the Financial Year 2023-24; Dr. Lal PathLabs Ltd - 539524 - Audited Financial Results For The Quarter And Financial Year Ended March 31, 2023
Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia considered and approved the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/ Analysts to be held on Thursday, May 11, 2023 at 4:30 P.M. (IST) to discuss the financial and operating performance for Q4 & FY23. Dr. Lal PathLabs Ltd - 539524 - Board Meeting Intimation for Approval Of Audited (Standalone & Consolidated) Financial Results For The Period Ended March 31, 2023 And To Consider Recommending Final Dividend, If Any
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2023 ,inter alia, to consider and approve Audited (Standalone & Consolidated) Financial Results for the period ended March 31, 2023 and to consider recommending Final Dividend, if any Dr. Lal PathLabs Ltd - 539524 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Dr. Lal PathLabs Ltd 2 CIN NO. L74899DL1995PLC065388 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-23, 2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)NA Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Vinay GujralDesignation :-Compliance Officer Name of the Chief Financial Officer :- Ved Prakash Goel Designation : -Group Chief Financial Officer Date: 28/04/2023 Dr. Lal PathLabs Ltd - 539524 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyDr. Lal PathLabs Ltd 2CIN NO.L74899DL1995PLC065388 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 166.67 4Highest Credit Rating during the previous FY AAstable 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Vinay Gujral Designation: Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Ved Prakash Goel Designation: Group Chief Financial Officer EmailId: [email protected] Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.